Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Inhibitors of xanthine oxidase: scaffold diversity and structure-based drug design.

Mancera RL, Luna G, Dolzhenko AV.

ChemMedChem. 2019 Feb 10. doi: 10.1002/cmdc.201900034. [Epub ahead of print]

PMID:
30740924
2.

3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout.

Lü JM, Yao Q, Chen C.

Biochem Pharmacol. 2013 Nov 1;86(9):1328-37. doi: 10.1016/j.bcp.2013.08.011. Epub 2013 Aug 30.

3.

Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.

Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA.

Life Sci. 2005 Mar 4;76(16):1835-47. Epub 2005 Jan 18.

PMID:
15698861
4.

Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity.

Šmelcerović A, Tomović K, Šmelcerović Ž, Petronijević Ž, Kocić G, Tomašič T, Jakopin Ž, Anderluh M.

Eur J Med Chem. 2017 Jul 28;135:491-516. doi: 10.1016/j.ejmech.2017.04.031. Epub 2017 Apr 19. Review.

PMID:
28478180
5.

[Design, synthesis and biological evaluation of oxadiazole derivatives as xanthine oxidase inhibitors].

Yan DA, Zhang L, Tian JY, Ye F, Xiao ZY.

Yao Xue Xue Bao. 2016 Jun;51(6):954-60. Chinese.

PMID:
29879350
6.

Discovery of 2-phenylthiazole-4-carboxylic acid, a novel and potent scaffold as xanthine oxidase inhibitors.

Xu X, Deng L, Nie L, Chen Y, Liu Y, Xie R, Li Z.

Bioorg Med Chem Lett. 2019 Feb 15;29(4):525-528. doi: 10.1016/j.bmcl.2019.01.005. Epub 2019 Jan 7.

PMID:
30630716
7.

Synthesis, structure-activity relationships, and mechanistic studies of 5-arylazo-tropolone derivatives as novel xanthine oxidase (XO) inhibitors.

Sato D, Kisen T, Kumagai M, Ohta K.

Bioorg Med Chem. 2018 Jan 15;26(2):536-542. doi: 10.1016/j.bmc.2017.12.017. Epub 2017 Dec 13.

PMID:
29274704
8.

An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).

Ojha R, Singh J, Ojha A, Singh H, Sharma S, Nepali K.

Expert Opin Ther Pat. 2017 Mar;27(3):311-345. doi: 10.1080/13543776.2017.1261111. Epub 2016 Nov 28. Review.

PMID:
27841045
9.

Linking uric acid metabolism to diabetic complications.

Kushiyama A, Tanaka K, Hara S, Kawazu S.

World J Diabetes. 2014 Dec 15;5(6):787-95. doi: 10.4239/wjd.v5.i6.787. Review.

10.

Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.

Ernst ME, Fravel MA.

Clin Ther. 2009 Nov;31(11):2503-18. doi: 10.1016/j.clinthera.2009.11.033. Review.

PMID:
20109996
11.

The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.

Nakatsu Y, Seno Y, Kushiyama A, Sakoda H, Fujishiro M, Katasako A, Mori K, Matsunaga Y, Fukushima T, Kanaoka R, Yamamotoya T, Kamata H, Asano T.

Am J Physiol Gastrointest Liver Physiol. 2015 Jul 1;309(1):G42-51. doi: 10.1152/ajpgi.00443.2014. Epub 2015 May 21.

12.

6-(N-benzoylamino)purine as a novel and potent inhibitor of xanthine oxidase: inhibition mechanism and molecular modeling studies.

Tamta H, Thilagavathi R, Chakraborti AK, Mukhopadhyay AK.

J Enzyme Inhib Med Chem. 2005 Aug;20(4):317-24.

PMID:
16206825
13.

Inappropriate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry.

Pasina L, Brucato AL, Djade CD, Di Corato P, Ghidoni S, Tettamanti M, Franchi C, Salerno F, Corrao S, Marengoni A, Marcucci M, Mannucci PM, Nobili A; REPOSI Investigators.

Eur J Clin Pharmacol. 2014 Dec;70(12):1495-503. doi: 10.1007/s00228-014-1752-4. Epub 2014 Sep 18.

PMID:
25228251
14.

Synthesis, molecular docking and xanthine oxidase inhibitory activity of 5-aryl-1H-tetrazoles.

Fatima I, Zafar H, Khan KM, Saad SM, Javaid S, Perveen S, Choudhary MI.

Bioorg Chem. 2018 Sep;79:201-211. doi: 10.1016/j.bioorg.2018.04.021. Epub 2018 May 1.

PMID:
29772470
15.

Novel insights into the inhibitory mechanism of kaempferol on xanthine oxidase.

Wang Y, Zhang G, Pan J, Gong D.

J Agric Food Chem. 2015 Jan 21;63(2):526-34. doi: 10.1021/jf505584m. Epub 2015 Jan 7.

PMID:
25539132
16.

The screening and characterization of 6-aminopurine-based xanthine oxidase inhibitors.

Hsieh JF, Wu SH, Yang YL, Choong KF, Chen ST.

Bioorg Med Chem. 2007 May 15;15(10):3450-6. Epub 2007 Mar 12.

PMID:
17379526
17.

Xanthine oxidase inhibitory activity of nicotino/isonicotinohydrazides: A systematic approach from in vitro, in silico to in vivo studies.

Zafar H, Hayat M, Saied S, Khan M, Salar U, Malik R, Choudhary MI, Khan KM.

Bioorg Med Chem. 2017 Apr 15;25(8):2351-2371. doi: 10.1016/j.bmc.2017.02.044. Epub 2017 Feb 28.

PMID:
28302506
18.

Potential xanthine oxidase inhibitory activity of endophytic Lasiodiplodia pseudotheobromae.

Kapoor N, Saxena S.

Appl Biochem Biotechnol. 2014 Jul;173(6):1360-74. doi: 10.1007/s12010-014-0927-x. Epub 2014 May 7.

PMID:
24801403
19.

2-Benzamido-4-methylthiazole-5-carboxylic Acid Derivatives as Potential Xanthine Oxidase Inhibitors and Free Radical Scavengers.

Ali MR, Kumar S, Afzal O, Shalmali N, Ali W, Sharma M, Bawa S.

Arch Pharm (Weinheim). 2017 Feb;350(2). doi: 10.1002/ardp.201600313. Epub 2017 Jan 30.

PMID:
28133790
20.

Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment.

Zhao L, Roche BM, Wessale JL, Kijtawornrat A, Lolly JL, Shemanski D, Hamlin RL.

Life Sci. 2008 Feb 27;82(9-10):495-502. doi: 10.1016/j.lfs.2007.12.010. Epub 2008 Jan 24.

PMID:
18215719

Supplemental Content

Support Center